Trial Profile
A Phase 1 Double-Blind, Randomised, Two-Treatment Cross-over Study Comparing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF530 and Betaferon Administered by Subcutaneous Injection in Healthy Adult Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Interferon beta-1b (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Pelican Expression Technology; Pfenex
- 13 Nov 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 18 Jun 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 14 May 2015 Planned number of patients changed from 48 to 12 as per Australian New Zealand Clinical Trials Registry.